Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01648790 · ClinicalTrials.gov registry record · Phase 1
A Study of Prasugrel in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01648790 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 20 participants.
The verdict
NCT01648790, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the amount of drug available in the body when given to healthy participants as two different formulations with or without a meal. In addition, this study will evaluate how much of the drug gets into the blood stream and how long the body takes to get rid of it. Information about any side effects that may occur will also be collected. Each participant will receive a total of five different treatments. Each treatment is given by mouth, once a day. The treatment period lasts for five consecutive days.
Interventions
- DRUG Prasugrel ODT1 - Tablet
- DRUG Prasugrel ODT2 - Tablet
- DRUG Prasugrel ODT2 - Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01648790
The ClinicalTrials.gov registry entry for NCT01648790 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Prasugrel ODT1 - Tablet is the first listed.
NCT01648790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01648790 about?
NCT01648790 is a clinical study titled "A Study of Prasugrel in Healthy Participants". The purpose of this study is to evaluate the amount of drug available in the body when given to healthy participants as two different formulations with or without a meal. In addition, this study will evaluate how much of the drug gets into the blood stream and how long the body takes to get rid of i...
What is the current status of trial NCT01648790?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2012-07. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01648790?
The interventions under investigation include: Prasugrel ODT1 - Tablet (DRUG), Prasugrel ODT2 - Tablet (DRUG), Prasugrel ODT2 - Suspension (DRUG).
Who is sponsoring clinical trial NCT01648790?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.